Lutetium-177 PSMA therapie voor patiënten met prostaatkanker – een kort overzicht van de literatuur

Ludwike W.M. van Kalmthout; Esmée C.A. van der Sar; Arthur J.A.T. Braat; Bart de Keizer; Marnix G.E.H. Lam

doi:10.1007/s13629-020-00300-z

Lutetium-177 PSMA therapie voor patiënten met prostaatkanker – een kort overzicht van de literatuur

Translated title of the contribution: Lutetium-177-PSMA therapy for prostate cancer patients—a brief overview of the literature

Ludwike W.M. van Kalmthout^*, Esmée C.A. van der Sar, Arthur J.A.T. Braat, Bart de Keizer, Marnix G.E.H. Lam

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

86 Downloads (Pure)

Abstract

Radioligand therapy with lutetium-177 prostate specific membrane antigen ([¹⁷⁷Lu]Lu-PSMA) represents a promising treatment for metastatic castration-resistant prostate cancer patients. In this paper, we aim to summarize the current knowledge derived from the literature as well as the authors’ experiences on [¹⁷⁷Lu]Lu-PSMA therapy. Various systematic reviews, mostly including small retrospective studies, summarized efficacy and oncological outcomes of [¹⁷⁷Lu]Lu-PSMA therapy. Any therapy-related prostate-specific antigen (PSA) response was reported in the majority of the patients (68–75%); >50% PSA decline was demonstrated in 34.5–51% of the patients. Incidence of side effects was low and in most patients, hematological toxicity remained limited to Common Terminology Criteria for Adverse Events (CTCAE) grade 1–2. Also, favorable efficacy was shown with regard to tumor response on imaging, pain symptoms and quality of life. In the near future, results of the awaited pivotal prospective studies (NCT03511664, NCT03392428) will define efficacy of [¹⁷⁷Lu]Lu-PSMA therapy and its oncological value for metastatic castration-resistant prostate cancer patients.

Translated title of the contribution	Lutetium-177-PSMA therapy for prostate cancer patients—a brief overview of the literature
Original language	Dutch
Pages (from-to)	141-146
Number of pages	6
Journal	Tijdschrift voor Urologie
Volume	10
Issue number	6-7
DOIs	https://doi.org/10.1007/s13629-020-00300-z
Publication status	Published - 1 Oct 2020

Keywords

Castration-resistant prostate cancer
Radioligand therapy
[Lu]Lu-PSMA

Access to Document

10.1007/s13629-020-00300-z

Kalmthout2020_Article_Lutetium-177-PSMATherapyForProFinal published version, 392 KB

Cite this

@article{9f14193542884183a6469fe693b4616d,

title = "Lutetium-177 PSMA therapie voor pati{\"e}nten met prostaatkanker – een kort overzicht van de literatuur",

abstract = "Radioligand therapy with lutetium-177 prostate specific membrane antigen ([177Lu]Lu-PSMA) represents a promising treatment for metastatic castration-resistant prostate cancer patients. In this paper, we aim to summarize the current knowledge derived from the literature as well as the authors{\textquoteright} experiences on [177Lu]Lu-PSMA therapy. Various systematic reviews, mostly including small retrospective studies, summarized efficacy and oncological outcomes of [177Lu]Lu-PSMA therapy. Any therapy-related prostate-specific antigen (PSA) response was reported in the majority of the patients (68–75%); >50% PSA decline was demonstrated in 34.5–51% of the patients. Incidence of side effects was low and in most patients, hematological toxicity remained limited to Common Terminology Criteria for Adverse Events (CTCAE) grade 1–2. Also, favorable efficacy was shown with regard to tumor response on imaging, pain symptoms and quality of life. In the near future, results of the awaited pivotal prospective studies (NCT03511664, NCT03392428) will define efficacy of [177Lu]Lu-PSMA therapy and its oncological value for metastatic castration-resistant prostate cancer patients.",

keywords = "Castration-resistant prostate cancer, Radioligand therapy, [Lu]Lu-PSMA",

author = "{van Kalmthout}, {Ludwike W.M.} and {van der Sar}, {Esm{\'e}e C.A.} and Braat, {Arthur J.A.T.} and {de Keizer}, Bart and Lam, {Marnix G.E.H.}",

year = "2020",

month = oct,

day = "1",

doi = "10.1007/s13629-020-00300-z",

language = "Dutch",

volume = "10",

pages = "141--146",

journal = "Tijdschrift voor Urologie",

issn = "2211-3037",

publisher = "Springer Science + Business Media",

number = "6-7",

}

TY - JOUR

T1 - Lutetium-177 PSMA therapie voor patiënten met prostaatkanker – een kort overzicht van de literatuur

AU - van Kalmthout, Ludwike W.M.

AU - van der Sar, Esmée C.A.

AU - Braat, Arthur J.A.T.

AU - de Keizer, Bart

AU - Lam, Marnix G.E.H.

PY - 2020/10/1

Y1 - 2020/10/1

N2 - Radioligand therapy with lutetium-177 prostate specific membrane antigen ([177Lu]Lu-PSMA) represents a promising treatment for metastatic castration-resistant prostate cancer patients. In this paper, we aim to summarize the current knowledge derived from the literature as well as the authors’ experiences on [177Lu]Lu-PSMA therapy. Various systematic reviews, mostly including small retrospective studies, summarized efficacy and oncological outcomes of [177Lu]Lu-PSMA therapy. Any therapy-related prostate-specific antigen (PSA) response was reported in the majority of the patients (68–75%); >50% PSA decline was demonstrated in 34.5–51% of the patients. Incidence of side effects was low and in most patients, hematological toxicity remained limited to Common Terminology Criteria for Adverse Events (CTCAE) grade 1–2. Also, favorable efficacy was shown with regard to tumor response on imaging, pain symptoms and quality of life. In the near future, results of the awaited pivotal prospective studies (NCT03511664, NCT03392428) will define efficacy of [177Lu]Lu-PSMA therapy and its oncological value for metastatic castration-resistant prostate cancer patients.

AB - Radioligand therapy with lutetium-177 prostate specific membrane antigen ([177Lu]Lu-PSMA) represents a promising treatment for metastatic castration-resistant prostate cancer patients. In this paper, we aim to summarize the current knowledge derived from the literature as well as the authors’ experiences on [177Lu]Lu-PSMA therapy. Various systematic reviews, mostly including small retrospective studies, summarized efficacy and oncological outcomes of [177Lu]Lu-PSMA therapy. Any therapy-related prostate-specific antigen (PSA) response was reported in the majority of the patients (68–75%); >50% PSA decline was demonstrated in 34.5–51% of the patients. Incidence of side effects was low and in most patients, hematological toxicity remained limited to Common Terminology Criteria for Adverse Events (CTCAE) grade 1–2. Also, favorable efficacy was shown with regard to tumor response on imaging, pain symptoms and quality of life. In the near future, results of the awaited pivotal prospective studies (NCT03511664, NCT03392428) will define efficacy of [177Lu]Lu-PSMA therapy and its oncological value for metastatic castration-resistant prostate cancer patients.

KW - Castration-resistant prostate cancer

KW - Radioligand therapy

KW - [Lu]Lu-PSMA

UR - http://www.scopus.com/inward/record.url?scp=85089897156&partnerID=8YFLogxK

U2 - 10.1007/s13629-020-00300-z

DO - 10.1007/s13629-020-00300-z

M3 - Article

AN - SCOPUS:85089897156

SN - 2211-3037

VL - 10

SP - 141

EP - 146

JO - Tijdschrift voor Urologie

JF - Tijdschrift voor Urologie

IS - 6-7

ER -

Lutetium-177 PSMA therapie voor patiënten met prostaatkanker – een kort overzicht van de literatuur

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this